Lefuma 10mg Tablet contains Leflunomide, an immunomodulatory agent primarily used in the management of rheumatoid arthritis and psoriatic arthritis. Leflunomide exerts its therapeutic effect by inhibiting dihydroorotate dehydrogenase, a key enzyme involved in pyrimidine synthesis, thereby reducing the proliferation of activated lymphocytes responsible for inflammatory responses. This mechanism helps to alleviate joint inflammation, pain, and swelling, ultimately improving physical function and quality of life in affected patients. Lefuma 10mg is indicated for adults with active rheumatoid arthritis who have shown inadequate response to conventional disease-modifying antirheumatic drugs (DMARDs). The tablet should be administered orally, with dosing individualized based on clinical response and tolerability. Common adverse effects include gastrointestinal disturbances such as diarrhea, nausea, and abdominal pain, as well as elevated liver enzymes, alopecia, and rash. Regular monitoring of liver function tests, complete blood counts, and renal function is recommended during therapy to detect potential toxicity early. Lefuma is contraindicated in pregnancy due to teratogenic risks and should be used with caution in patients with pre-existing liver disease. Patients should be advised to avoid live vaccines while on treatment and to inform healthcare providers of all concomitant medications to prevent drug interactions.